Medicenna Therapeutics Corp. is a clinical-stage biotechnology company specializing in the development of advanced immunotherapies for cancer and other challenging diseases. Leveraging its proprietary Superkine Platform, Medicenna engineers powerful and highly selective interleukin-based therapeutics known as Superkines. These novel proteins are designed to precisely modulate and amplify the immune response, targeting key cellular pathways to enhance anti-tumor immunity or address autoimmune conditions. The company’s pipeline includes Superkines such as MDNA11, an engineered IL-2 variant optimized for cancer immunotherapy, and MDNA55, an IL-4 empowered cytotoxin developed for recurrent glioblastoma, a form of brain cancer. Additional candidates address various solid tumors and autoimmune diseases, utilizing mechanisms that either stimulate immune cell activity or inhibit disease-promoting cytokine signaling. Medicenna’s innovative technologies are geared toward tackling diseases with significant unmet need, emphasizing scientific rigor and patient-centered outcomes. The company maintains a focused mission to transform the therapeutic landscape through next-generation immunotherapies, underpinned by a commitment to advancing cytokine biology and translational medicine.